miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models.
about
Multiple Aspects of Gene Dysregulation in Huntington's DiseaseThe involvement of microRNAs in neurodegenerative diseasesUtility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological DisordersReversal of cellular phenotypes in neural cells derived from Huntington's disease monkey-induced pluripotent stem cellsMicroRNAs located in the Hox gene clusters are implicated in huntington's disease pathogenesis.miR-10b-5p expression in Huntington's disease brain relates to age of onset and the extent of striatal involvementThe Potential Regulatory Mechanisms of miR-196a in Huntington's Disease through Bioinformatic AnalysesLung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16.miR-196a Ameliorates Cytotoxicity and Cellular Phenotype in Transgenic Huntington's Disease Monkey Neural CellsmiRNAs: Key Players in Neurodegenerative Disorders and EpilepsyIntegrated analysis of microRNAs and their disease related targets in the brain of mice infected with West Nile virus.Large Animal Models of Huntington's Disease.Neuroprotective effects of psychotropic drugs in Huntington's diseaseInduced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.iPSC-based drug screening for Huntington's disease.microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases.Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.Huntington Disease as a Neurodevelopmental Disorder and Early Signs of the Disease in Stem Cells.MicroRNAs in Neurocognitive Dysfunctions: New Molecular Targets for Pharmacological Treatments?Modeling simple repeat expansion diseases with iPSC technology.Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity.The Differential Profiling of Ubiquitin-Proteasome and Autophagy Systems in Different Tissues before the Onset of Huntington's Disease Models.Generation of Cholinergic and Dopaminergic Interneurons from Human Pluripotent Stem Cells as a Relevant Tool for In Vitro Modeling of Neurological Disorders Pathology and Therapy.miRNAs as biomarkers of neurodegenerative disorders.Role of miRNAs in human disease and inborn errors of metabolism.The Ubiquitin Receptor ADRM1 Modulates HAP40-Induced Proteasome Activity.miR-196a Enhances Neuronal Morphology through Suppressing RANBP10 to Provide Neuroprotection in Huntington's Disease.MicroRNA in neurodegenerative drug discovery: the way forward?Epigenetic profiles in polyglutamine disorders.Representing Diversity in the Dish: Using Patient-Derived in Vitro Models to Recreate the Heterogeneity of Neurological Disease.Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.MicroRNA Profiling Identifies miR-196a as Differentially Expressed in Childhood Adrenoleukodystrophy and Adult Adrenomyeloneuropathy.microRNAs in Neurodegeneration: Current Findings and Potential Impacts.
P2860
Q24605880-FBF6B352-F9AE-4959-A6B1-C420CFCCF5F7Q26858788-B0717670-D594-4C1F-962B-61E645C13BF3Q28080219-1605C965-2476-4162-9C40-25DE13D6DF41Q34469493-D44062BC-312B-4271-B62C-608E0D0AA42AQ35105770-7999B1C7-8A88-4E7B-BD68-F1FAD1286087Q35147342-29ED140C-CD07-42DD-81EE-285272F4845DQ35777465-5BA63DE5-81D6-4011-8AF5-61F9408EB6F0Q35832959-9290DF5E-38F9-43F9-994B-AFC6D918A800Q36133682-00D41B86-E6B5-4CA7-AD00-2BFC6790C2C4Q37535111-A4B6B941-F389-41FB-8269-9EFB7039739FQ37646515-457D2D21-983A-46FD-96CD-9F314FB361B8Q38139322-344B3637-B786-4AF3-9A6F-2E0247ACD6C2Q38163877-D57682BF-76E7-48C7-A84A-7D9A4DB0D0EDQ38242113-8EB422AD-1E0C-4F92-BAE3-5C2A928E43B7Q38597179-72ABDFBD-ACA3-4F68-AAAC-054D746BA18FQ38648154-DE77D59D-8DFB-4EB3-B29B-273433FDA462Q38714908-F25AA5B5-E4E7-4FC5-A991-7A1B5918D961Q38790183-4FDDAEAA-A7F0-42C1-A4B0-7F46B580D4E2Q38843644-A0A6397C-5B45-4D81-846B-7D3DBEC90586Q38853911-06BF8FE5-C1C5-4F1F-9699-194D6DD78D1CQ38884155-BFA0E212-CEB7-4E15-AF8F-77DE1F43C92AQ38960787-3378E25D-F65D-493C-BEE5-867B46E058CCQ39095805-37D50262-6358-43DC-ADDB-152B6EA0D852Q39104808-252D8D91-96BD-4A12-82E0-FE9E73935A55Q39147403-88F912B7-24EA-45AC-A0AE-322E284B0720Q39213276-6166AB00-44FA-4640-8102-7D5FFF0F4472Q41114302-746BF9E3-5BB6-4A4D-AE8D-5BA6D80FA6C6Q48453741-B00573A2-B67F-4041-9EB7-367632CE9015Q49668183-BAA51BDB-514D-487E-9653-4198116ECA08Q50322422-38C3692A-432B-4410-A99E-AC0A823850B3Q52605399-A3C84F2B-C161-40D9-8323-320AB07580A7Q53276010-27E58602-3262-4B0B-B2CC-FB86117A78EFQ55231712-A854A9A9-16C5-4775-B8DB-4E483B649443
P2860
miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
miR-196a ameliorates phenotype ...... pluripotent stem cell models.
@en
miR-196a ameliorates phenotype ...... pluripotent stem cell models.
@nl
type
label
miR-196a ameliorates phenotype ...... pluripotent stem cell models.
@en
miR-196a ameliorates phenotype ...... pluripotent stem cell models.
@nl
prefLabel
miR-196a ameliorates phenotype ...... pluripotent stem cell models.
@en
miR-196a ameliorates phenotype ...... pluripotent stem cell models.
@nl
P2093
P2860
P1476
miR-196a ameliorates phenotype ...... d pluripotent stem cell models
@en
P2093
Anthony W S Chan
Chia-Ling Li
Chuan-Mu Chen
Pei-Hsun Cheng
Shang-Hsun Yang
Yen-Yu Lai
Yu-Fan Chang
P2860
P304
P356
10.1016/J.AJHG.2013.05.025
P407
P577
2013-06-27T00:00:00Z